Specification
[ CAS No.: 138926-19-9 ]
Ibandronate sodium monohydrate
 |
CAS No. : | 138926-19-9 |
| Cat. No. : | A183108 | |
| Formula : | C9H24NNaO8P2 | |
| Purity : | 98% | |
| M.W : | 359.23 g/mol | |
| Synonyms : |
1. Ibandronate Sodium Monohydrate |
|
| MDL No. : | MFCD00912167 | |
| Storage : | Keep in dark place, sealed in dry, 2-8°C | |
| InChI Key : | OC(P(O)(O[Na])=O)(CCN(CCCCC)C)P(O)(O)=O.O | |
| Pubchem ID : | 23663991 | |
| Linear Structure Formula : | - | |
| Boiling Point : | - |
| Safety of [ 138926-19-9 ] | |||
|---|---|---|---|
| Signal Word : | Danger | Class : | 8 |
| Precautionary Statements : | P260-P264-P270-P273-P280-P301+P312+P330-P301+P330+P331-P303+P361+P353-P304+P340+P310-P305+P351+P338+P310-P314-P363-P391-P405-P501 | UN# : | 1759 |
| Hazard Statements : | H302-H314-H373-H410 | Packing Group : | Ⅱ |
| GHS Pictogram : |
|
||
| Biological Activity of [ 138926-19-9 ] | |
|---|---|
| Description : |
Ibandronate Sodium Monohydrate is a potent nitrogen-containing bisphosphonate, primarily utilized in the treatment of osteoporosis. It operates by targeting the bone metabolism to prevent bone loss. In research focused on endothelial cells, Ibandronate at concentrations between 1.25 and 2 μM notably reduces cell growth. At 2 μM, it also significantly hampers the formation of capillary-like structures and induces apoptosis in these cells. Furthermore, Ibandronate increases VEGF expression in endothelial cells in a dose-dependent manner when administered at concentrations below 100 μM[1].
Show More |